

<b>NCT ID</b>	NCT04730544
<b>Title</b>	Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-01-29
<b>Location</b>	France
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, Nivolumab
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT04724239
<b>Title</b>	A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-01-26
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	chidamide, IBI305, Sintilimab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04708470
<b>Title</b>	Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2021-01-14
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bintrafusp alfa, Entinostat, NHS-IL12
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04687631
<b>Title</b>	Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
<b>Phase</b>	Phase 3
<b>Date Added</b>	2020-12-29
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04660812
<b>Title</b>	An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
<b>Phase</b>	Phase 1, Phase 2

<b>Date Added</b>	2020-12-09
<b>Location</b>	Alabama, United States Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy Korea, Republic of Spain United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04659382
<b>Title</b>	Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Checkpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-12-09
<b>Location</b>	France
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Atezolizumab, Bevacizumab, TheraSphere, XELOX
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04653480
<b>Title</b>	Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-12-04
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Chemotherapy, Surufatinib, Toripalimab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04626635
<b>Title</b>	REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2020-11-12

<b>Location</b>	California, United States
	Florida, United States
	Illinois, United States
	Iowa, United States
	Massachusetts, United States
	Michigan, United States
	New Jersey, United States
	New York, United States
	Ohio, United States
	Pennsylvania, United States
	Tennessee, United States
	Texas, United States
	Wisconsin, United States
	France
	Israel
	Netherlands
	Poland
	Spain
	Turkey
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	cemiplimab, REGN7075
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04607421
<b>Title</b>	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2020-10-29

<b>Location</b>	Arizona, United States California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04599140
<b>Title</b>	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
<b>Phase</b>	Phase 1
<b>Date Added</b>	2020-10-22
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting

Drugs

CXCR1/2 Inhibitor SX-682, Nivolumab

Tags

MSS/ MMRp